{
  "nctId": "NCT01917136",
  "briefTitle": "11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension",
  "officialTitle": "Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI",
  "protocolDocument": {
    "nctId": "NCT01917136",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2014-04-11",
    "uploadDate": "2018-11-29T23:26",
    "size": 289746,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01917136/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 21,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-08",
    "completionDate": "2018-10",
    "primaryCompletionDate": "2018-10",
    "firstSubmitDate": "2013-08-03",
    "firstPostDate": "2013-08-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nParticipation in the companion treatment protocol \"A randomized, double-blind, placebo controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction\"\n\nExclusion Criteria:\n\n* Pregnancy or lactation: Women of childbearing potential must have a negative urine or blood pregnancy test on the day of the PET/CT scan.\n* Severe anxiety or claustrophobia prohibiting completion of imaging\n* Inability to tolerate imaging procedures (1 hour MRI, 30 min and 15 min PET)\n* Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any other contraindication to MRI.\n* Uncontrolled diabetes mellitus with fasting glucose \\> 150 mg/dL",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Changes in RV Function",
        "description": "RV function as measured by cardiac MRI",
        "timeFrame": "6 months"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 14,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:29:13.364Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}